Protein phosphatase 1 (PP1) is the major isotype of serine/threonine phosphatase in cardiomyocytes, and its activity has been thought to be important for heart failure progression. The PP1 catalytic subunits consist of three distinct genes, PP1a, PP1b/d, and PP1g. To date, the function of each PP1 isoform is not well characterized in cardiomyocytes. We sought to determine the functional contribution of each PP1 isoform to sarcoplasmic reticulum (SR)-mediated Ca 2+ cycling in isolated adult rat cardiomyocytes.
Introduction
The b-adrenergic system is the most powerful regulator of cardiac contraction and relaxation in the heart. Adrenergic stimulation leads to the activation of intracellular key kinases, such as A-kinase (PKA) and calcium/calmodulin-dependent kinase II (CAMKII), followed by target protein phosphorylations in the plasmalemma and sarcoplasmic reticulum (SR) and enhancement of intracellular Ca 2+ cycling, resulting in positive inotropic and lusitropic actions of the heart. 1 On the other hand, these phosphorylation events are reversibly regulated by protein phosphatases (PPs). 2, 3 Cardiac PPs consist mainly of PP1, PP2A, and PP2B. We and others have shown that increased PP1 activity is closely associated with the progression of heart failure, 4 and could be a potential therapeutic target. 4 -7 The PP1 catalytic subunit consists of three distinct genes:
pp1ca (PP1a), ppp1cb (PP1b/d), and ppp1cc (PP1g), 8 whose functions
are not well characterized in cardiomyocytes. These three catalytic subunits have 90% homology in the catalytic domain and 10% † These two authors contributed equally.
distinct sequences in the N and C termini, characteristics that are believed to be important for substrate and tissue specificities. 9 Indeed, in non-cardiomyocyte experiments, it was reported that the three PP1 catalytic subunits were differentially distributed in HeLa cells, 10, 11 and each subunit governed a different cellular function.
Earlier microarray analysis using failing human hearts revealed that PP1a and PP1g mRNA were downregulated, whereas that of PP1b was upregulated, in end-stage dilated cardiomyopathy. 12 We therefore hypothesized that each PP1 catalytic subunit has a specific role in both the normal and diseased hearts. The present study was designed to isolate PP1 isoform-specific function and to correlate this function with SR-mediated Ca 2+ cycling in normal rat cardiomyocytes by using short hairpin RNA (shRNA)-mediated RNA interference technique. We found that PP1b is the most significantly involved isoform in regulating SR Ca 2+ uptake in cultured cardiomyocytes.
Methods
An extended version of Methods is available in Supplementary material online.
Animals
All animal protocols were approved by the Yamaguchi University School of Medicine Animal Experiment Committee. The animals were treated according to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) . Isolated adult rat left ventricular cardiomyocytes were prepared from normal male Wistar rats (6 -8 weeks old, Japan SLC, Hamamatsu, Japan) as described previously. 13 Male beagle dogs were anaesthetized by intravenous administration of thiopental (10 mg/kg) and ventilated, and the heart excised for further purification of cardiac SR.
Adenoviruses for shRNA vectors
Adenovirus (AdV) vectors encoding shRNA were designed to obtain a vector-based knockdown of PP1 isoforms. Briefly, self-annealing oligonucleotides for shRNA were designed using a web-based tool from Invitrogen (Carlsbad, CA, USA); target sense sequences (21 nt) of shRNA were inserted into the shRNA expression vector, pAdU6 (described in detail in Supplementary material online), followed by transfection of AdVs into HEK293 cells, as described previously. 14 A scrambled PP1 shRNA sequence was used as a negative control vector (AdV.PP1-SCR). Among the AdV shRNA vectors created (two to three targets for each PP1 isoform shRNA), the following AdV.shRNA vectors were used for the PP1 isoform-specific knockdown experiment, as they showed significantly reduced protein levels without affecting the expression of other PP1 isoforms: AdV.PP1a-shRNA (position 382 of the PP1a mRNA) for PP1a RNAi, AdV.PP1b-shRNA (position 738 of the PP1b mRNA) for PP1b RNAi, and AdV.PP1g-shRNA (position 829 of the PP1g mRNA) for PP1g RNAi.
Quantification of PP1 isoform expression
Cardiomyocytes were transfected with the AdVs at an MOI of 20, 200, and 500, and cultured for 24 -72 h at 378C in 5%CO 2 /95%O 2 atmosphere. Cells were lysed with an ice-cold buffer containing (in mM) 25 Tris -HCl (pH 7.4), 1 EDTA, 1 EGTA, 50 NaCl, 1 DTT, 1 Na 3 VO 4 , 1 PMSF, 1% PIC, 1% NP-40, and 0.5% Na-deoxycholate (RIPA buffer). Equal amounts of protein samples were prepared by adding an LDS buffer (Invitrogen). Samples were heated at 708C for 5 min, loaded on 10% bis-Tris gel (NuPage, Invitrogen), electrophophoresed, and transferred to a PVDF membrane. Expression levels were analysed by immunoblotting using each of the PP1 isoform-specific antibodies, followed by the incubation with secondary IgG conjugated to horse radish peroxidase. Chemiluminescence quantification was performed using Supersignal West Femto Substrate (Pierce, Rockford, IL, USA) followed by image analysis (LAS-4000, Fuji Film, Japan). Total RNAs of cardiomyocytes were prepared using an RNAeasy kit (Qiagen), and mRNA expression levels were analysed 48 h after AdV transfection by real-time RT -PCR (Lightcycler 1.5, Roche). The primer sets for RT -PCR are briefly described in Supplementary material online.
Immunoblot analysis of SR protein phosphorylation
For analysis of phosphorylation levels of SR proteins, cells were lysed in an ice-cold RIPA buffer containing 50 mM NaF, followed by quantitative immunoblotting using LAS-4000. The phosphorylation levels of phospholamban (PLN) at Ser16 and Thr17, that of ryanodine receptor (RyR) at Ser2808, and that of cardiac troponin I (TnI) at Ser22 and 23 were normalized to the total protein levels. To normalize the phosphorylation level of PLN at Ser16 in the different immunoblots among baseline, 10 nM and 1 mM isoproterenol (ISO) stimulation, we estimated the coefficient, using quantitative image analysis (LAS-4000) (Supplementary material online, Figure S1 ). We used the coefficients to scale the phosphorylation level in the different immunoblots. The SR Ca 2+ load was estimated as the peak fluorescence signal of fura-2 ratio after a 1 Hz stimulation train by rapidly switching the superfusion solution to one containing 20 mM caffeine, as described previously. 15 The data obtained were further analysed by IONOPTIX software (Milton, MA, USA).
Dephosphorylation assay of SR Ca

regulatory proteins
Cardiomyocytes were infected with either AdV.PP1-shRNA or AdV.PP1-SCR (control vector) at an MOI of 500, incubated at 378C for 72 h, and then treated with 1 mM ISO for 1 h. Thereafter, cells were washed twice with ISO-free culture medium and harvested at 0, 5, 10, 20, 40, and 60 min, followed by analysis of the PLN phosphorylation levels (at Ser16 and Thr17) and RyR2 (at Ser2808).
AdV expression of EGFP-tagged PP1 isoform and pulldown of SR Ca 21 regulatory proteins
To characterize the physical interaction between each PP1 isoform and PLN/RyR in the SR, we created an AdV encoding an EGFP-tag for each PP1 isoform with a single amino acid mutation (D94/95N), and transfected each AdV into cardiomyocytes (details are provided in Supplementary material online). 16 Forty-eight hours after transfection, the cells were lysed with a solution containing 50 mM NaCl, 50 mM Tris (pH 7.4), 2 mM MgCl 2 , and 0.5% Triton X-100. EGFP-tagged PP1 protein complexes were purified with a mMACS green fluorescent protein (GFP)-tagged protein isolation kit (Miltenyi Biotec, Germany). The physical associations between EGFP-PP1 mutants and SR Ca 2+ regulatory proteins were further analysed.
Immunoprecipitation of PP1 and Ca
regulatory proteins
Cardiac microsomes were solubilized by the lysis solution. First, 150 mg of crude SR was pre-cleared with protein G sepharose (Amersham) for 30 min, and incubated with primary antibodies at 48C overnight followed by precipitation with protein G sepharose for 1 h. Immunoblot analyses were performed to determine the physical interaction between PP1 isoform and SR proteins, such as PLN, sarco-endoplasmic ATPase 2a (SERCA2a), and RyR.
Isolation of cardiac microsomes and purification of junctional and longitudinal SRs
Cardiac microsomes were prepared as described previously. 17 A centrifugation technique using two consecutive sucrose density gradients (the protocol is described in detail in Supplementary material online) in combination with Mg 2+ -ATP-dependent SR Ca 2+ overloading was employed to isolate two different fractions of the SR-the junctional and longitudinal SR-without significant contamination by other organelles, as was previously confirmed by electron microscopy. 18 
Antibodies
The following antibodies were obtained from commercially available sources: antibodies for PP1a (BD Biosciences, San Jose, CA, USA), PP1b (ab16369, ab53315), PP1g (ab26175, ab16387), and PLN (ab2865, clone 2D12) (Abcam, Cambridge, UK); phosphorylated PLN at Ser16, PLN, PKA catalytic subunit, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Chemicon International), phosphorylated PLN at Thr17, and phoshphorylated-RyR2 at Ser2808 (Badrilla, Leeds, UK); RyR2 and a-actinin (Sigma-Aldrich), SERCA2a (clone N-19; Santa Cruz Biotechnology, Santa Cruz, CA, USA), cardiac TnI (clone 19C7), and phospho-TnI at Ser22 and 23 (clone 5E6) (Genetex, San Antonio, TX, USA).
Statistical analysis
Comparisons between the two groups were performed by Student's t-test. Comparisons between repeated measurements were done with ANOVA, followed by the post hoc test (the Student -Newman -Keuls method was used to compare the two groups when appropriate). A value of P , 0.05 was considered statistically significant. Data are expressed as the mean + SEM.
Results
Efficiency of PP1 isoform-specific shRNA
AdVs encoding shRNA vectors for PP1a, PP1b/d, and PP1g were transfected into adult rat cardiomyocytes, and representative knockdown efficiency was shown at 0, 48, and 72 h after transfection on the protein expression level ( Figure 1A ). Expression levels in each PP1 isoform was most significantly reduced at 72 h. All PP1 isoformspecific PP1-shRNA vectors showed significant reduction ( Figure 1B : PP1a 59.1 + 3.0% vs. control; Figure 1C : PP1b 64.1 + 2.1% vs. control; Figure 1D : PP1g 77.7 + 3.4% vs. control) at 72 h, although PP1 isoform-specific SR regulation in cardiomyocytes the differences in shRNA efficiency among the three PP1 isoforms were not statistically significant. A significant shRNA effect in the mRNA level was also confirmed at 48 h after transfection (see Supplementary material online, Figure S2 ). In addition, those shRNA vectors did not induce a significant interferon response (see Supplementary material online, Figure S3 ), supporting the PP1-shRNA-mediated specific gene knockdown. None of the PP1 isoform shRNA had any effect on cell survival or the subcellular SR and Z-band structure, as assessed by immunofluorescence of RyR2, PLN, and a-actinin (Supplementary material online, Figure S4A ). None of the PP1 knockdown significantly altered PP1 activity in cardiomyocyte homogenates (Supplementary material online, Figure  S4B ), whereas AdV inhibitor-2 expression significantly depressed PP1 activity. Thus, the successful knockdown of each PP1 isoform was accomplished without affecting the expression of the other PP1 isoforms. Interestingly, none of the PP1 knockdowns affected the whole-cell PP1 activity in isolated rat cardiomyocytes, suggesting that there is a compensatory mechanism to maintain a constant level of whole-cell PP1 activity.
Effects of PP1-shRNA on phosphorylation levels of SR proteins
Although none of the individual PP1 knockdown effects altered whole-cell PP1 activity, the basal phosphorylation levels of PLN at Ser16 were significantly increased by PP1b-shRNA in an MOIdependent manner (Figure 2A , p16-PLN, arrows, and Figure 2B ). PP1a-shRNA also slightly increased PLN phosphorylation at Ser16 PP1 isoform-specific SR regulation in cardiomyocytes (small arrows), but the effect of PP1a-shRNA on PLN phosphorylation did not reach statistical significance (Figure 2A and B) . There were no changes in the expression levels in PLN, RyR, SERCA2a, and the PKA catalytic subunits, in phosphorylation levels of PLN at Thr17, cardiac TnI at Ser22 and 23, or RyR2 at Ser2808 (Figure 2A and see Supplementary material online, Figure S5 ) by AdV-mediated PP1-shRNA. There were no changes in the expression levels of PP1 endogenous inhibitors, namely inhibitor-1 and inhibitor-2 in PP1-shRNA-treated cardiomyocytes (Supplementary material online, Figure S6) . The increased phosphorylation level of PLN at Ser16 was further enhanced by PP1b-and PP1a-shRNA with low-dose ISO (10 nM) stimulation (Figure 2A middle, double arrows, and Figure 2C) . However, such enhancement effects became indistinguishable at highdose ISO (1 mM) (Figure 2A bottom and D) . These data indicate that PP1b-shRNA, and partially PP1a-shRNA, can alter phosphorylation balance of PLN at Ser16 without b-adrenergic stimulation in cultured cardiomyocyte.
PP1b-shRNA most effectively enhanced cell shortening and the Ca 21 transient
Among these PP1 knockdowns, the PP1b knockdown most effectively augmented the amplitude of Ca 2+ transient, %CS, positive (+dL/dt) and negative (2dL/dt) first derivatives of the cell length both at baseline and with low-dose ISO stimulation, as shown in Figure 3A -G. Although the PP1a and PP1g knockdowns also slightly enhanced %CS and the Ca 2+ transient, it was in both cases to a lesser extent than with PP1b ( Figure 3B -G) . To rule out the Ca 2+ buffering effects that the dye Fura-2 might have on the cell capacity to respond to stimulation, we also performed experiments in unloaded cells transfected with PP1b-shRNA. Under these experimental conditions, we observed similar enhancement of %CS (data not shown). Furthermore, the SR Ca 2+ load was significantly enhanced in PP1b-shRNA-treated cardiomyocytes but not in other PP1 isoform-shRNAs ( Figure 4A and B) , supporting the notion that PP1b-shRNA most significantly enhanced SR Ca 2+ uptake in cultured cardiomyocytes.
Effect of PP1b-shRNA dephosphorylation kinetics
As the PP1b knockdown most significantly enhanced SR Ca 2+ handling and increased PLN phosphorylation, we also assessed the kinetics of dephosphorylation in PLN and RyR, key proteins in SR Ca 2+ cycling, in PP1b-knockdown cardiomyocytes. As shown in Figure 4C , incubation with 1 mM ISO for 1 h largely phosphorylated PLN at Ser16 and RyR2 at Ser 2808. Thereafter, dephosphorylation levels were determined at each time point after ISO removal. In PP1b-shRNA cardiomyocytes, the time constant of dephosphorylation of PLN at Ser16 was slower than that of the control AdV.PP1-SCR-transfected cardiomyocytes ( Figure 4D ). The time courses of dephosphorylation of RyR at 2808 appeared to be unaffected by PP1b knockdown ( Figure 4E ). These data indicate that the kinetics of PLN dephosphorylation at Ser16 are also affected by PP1b-shRNA. According to these findings, we further hypothesized that PP1b was more selectively involved with SERCA2a and PLN than other PP1 isoforms in the longitudinal SR of cardiomyocytes.
SERCA and PLN preferentially interact with PP1b
To quantitatively compare the avidity of the PP1 isoforms for SERCA2a and PLN, AdVs expressing N-terminally EGFP-fused PP1a, PP1b, and PP1g with a single amino acid mutation (D94/95N; a catalytically inactive mutant 16 ) in their catalytic domains were transfected into cardiomyocytes, followed by purification with GFP antibody-binding microbeads and assessment of the physical interaction between PP1b and SERCA/PLN. As demonstrated in Figure 5A , EGFP-tagged PP1a, PP1b, and PP1g were exclusively detected by each PP1 isoform antibody, indicating the specificity of the antibodies. Interestingly, SERCA and PLN were most abundantly associated with EGFP-PP1b ( Figure 5B) . The higher avidity of PP1b for PLN in terms of the endogenous expression levels was also confirmed by using canine microsome (crude SR) preparations. PP1b and PLN were co-immunoprecipitated in 0.5% Triton X-100-solubilized canine SR preparations ( Figure 5C ) but the PP1a and PP1g antibodies were not, suggesting that endogenous PP1 preferentially interacts with PLN in the SR. In addition, RyR was co-immunoprecipitated with PP1b and PP1g, but not with PP1a, suggesting a differential physical interaction between PP1 catalytic subunits and both PLN and RyR in the SR.
Three PP1 isoforms are differentially distributed in the junctional and longitudinal SR
To further elucidate PP1 isoform-specific regulation of SR Ca 2+ cycling, intrinsic PP1 isoform distributions were further characterized in the canine SR, which were separated into plasmalemma, junctional SR, and longitudinal SR fractions. As we needed a large amount of heart tissue ( 120 g) for the SR subfractionation procedure, we used canine hearts instead of rat hearts for this analysis. In the crude SR, all PP1 isoforms were equally detected (Supplementary material online, Figures S7 and S8) by their specific antibodies. In the subfractionated SR ( Figure 6A) , PP1a was dominantly detected in the plasmalemma-rich fractions [fractions 1-3, as characterized by the enrichment of b-dystroglycan (b-DG) in Figure 6B ]. PP1b exhibited ubiquitous distribution throughout all of the SR fractions (fractions 1-6), and exhibited comparatively higher expression in the longitudinal SR fraction ( Figure 6B , indicated by the arrow in the lane of fraction 6). PP1g was highly enriched in the junctional SR ( Figure 6B , indicated by the double arrow in the lane of fraction 5). The contamination by mitochondria and myofibrillar fraction was almost negligible, as only a very faint band was detected in fractions 1-6 ( Figure 6B) .
These data indicate that the junctional SR contains a greater amount of PP1g and that the longitudinal SR contains a greater amount of PP1b.
Discussion
In the present study, we successfully achieved PP1 isoform-specific knockdown in cultured cardiomyocytes by using AdV PP1-shRNA vectors, and found that PP1b knockdown most significantly enhanced cell shortening and the Ca 2+ transient among the three PP1 isoforms.
Phosphorylation changes in PLN at Ser16, which were most significantly augmented by PP1b knockdown, at least partly explain the enhancement effect on cell shortening and the Ca 2+ transient. In addition, we found that PP1b displayed higher expression in the longitudinal SR, and formed a molecular complex with PLN and SERCA2a, supporting the notion that PP1b is the most significantly involved isoform in regulating SR Ca 2+ uptake. To our knowledge, this is the first demonstration of isoform-specific PP1 regulation of SR-mediated Ca 2+ cycling in cardiomyocytes.
The three PP1 isoforms have been shown to play distinct roles related to dephosphorylation targets in a variety of cell types. For example, PP1a has been shown to be most important for cell proliferation, 11 and PP1b has been shown to be important for glycogen metabolism and myosin phosphorylation, 9 whereas PP1g, including two alternative splice variants of PP1g1 and PP1g2, has been shown to play a specific role in spermatogenesis, apoptosis against oxidative stress in vascular smooth muscle, and neuronal function in a Parkinson disease model. 19, 20 In the heart, a previous study 21 revealed that the PP1a transcript appeared to be the highest among the three isoforms relative to the ribosomal RNA, followed by PP1g and then PP1b. As we were unable to measure any isoform-specific PP1 activity or quantify isoform-specific subcellular distribution by immunohistochemistry due to a lack of the appropriate antibodies, we chose shRNAmediated gene knockdown to compare isoform-specific PP1 function on SR-mediated Ca 2+ cycling. AdV-mediated shRNA successfully reduced the genetic expression of each PP1 (59-78% of control).
In particular, PP1a and PP1b were almost equally suppressed by shRNA knockdown at the protein expression level (59.1 + 3.0 and 64.1 + 2.1% vs. control, respectively). Nevertheless, PP1b-shRNA significantly augmented the %CS and Ca 2+ transient at baseline and with low-dose ISO, compared with PP1a-shRNA, strengthening the idea that PP1b has a higher impact than PP1a on SR Ca 2+ cycling.
Although the suppression of PP1g tended to be slightly higher than that of PP1a and that of PP1b at the protein level, its knockdown effect on Ca 2+ cycling and cell shortening was lower, suggesting a minor role in SR-mediated Ca 2+ cycling in cardiomyocytes.
PP1a also significantly enhanced Ca 2+ cycling and cell shortening at baseline and with low-dose ISO stimulation. One favoured explanation is that PP1a was slightly but significantly detected in the longitudinal and junctional SR, and has been reported to be the most abundant PP1 isoform among the three isoforms 21 in cardiomyocytes.
It is conceivable that PP1 function on SR Ca 2+ cycling is not exclusively governed by PP1b but in part regulated by PP1a. The whole-cell PP1 activity was not altered in any of PP1-shRNA-mediated knockdown. As PP1 catalytic subunits do not freely exist in the cell but are known to associate with a variety of regulatory subunits, the compensatory mechanism may be involved in the maintenance of the whole cellular PP1 activity constant. As previously reported from in vitro 11 and in vivo 20 experiments, certain parts of the PP1 isoform function can be compensated by other isoforms, supporting the fact that the whole-cell PP1 activity was kept constant in each PP1 isoform-specific knockdown. In addition, a lack of an effect of PP1-shRNA on the phosphorylation target, including RyR and TnI, also supports the fact that the whole-cell PP1 activity was not altered by PP1-shRNA. Nevertheless, PP1b-shRNA effectively augmented PLN phosphorylation at Ser16 at baseline and with low-dose ISO stimulation, suggesting that the subcellular microenvironment in the vicinity of PLN was significantly affected by PP1b-shRNA and partially by PP1a-shRNA. In this regard, it is intriguing that PP1-shRNA significantly increased PLN phosphorylation at Ser16 at baseline, although the phosphorylation of PLN at Thr17 was not detectable in cultured cardiomyocytes. These data also suggest that there is a significant PKA activity without b-adrenergic stimulation, but not CAMKII activity, in cultured cardiomyocytes.
On the other hand, PLN phosphorylation was not affected at highdose ISO stimulation in PP1-shRNA-treated cardiomyocytes. It is conceivable that the augmentation effect of PLN phosphorylation by PP1b-shRNA was not appreciable in the condition of maximally phosphorylated PLN at Ser16 with high-dose ISO stimulation. In addition, the dephosphorylation kinetics of PLN phosphorylation were significantly altered by PP1b-shRNA. These data suggest that PP1b not only determines the static levels of phosphorylation but also affects the dynamics of phosphorylation/dephosphorylation of PLN at Ser16 in cardiomyocytes. As PP1b expression has been shown to gradually increase during the progressive time course of cardiac dysfunction in cardiomyopathic hamsters, the expression levels of PP1b may have a significant impact on SR Ca 2+ cycling. 4 We found that there is a differential PP1 isoform-specific distribution in the longitudinal and junctional SR in cardiomyocytes ( Figure 6 ). In particular, PP1b was comparatively enriched in the longitudinal SR, and formed a molecular complex with PLN and SERCA2a, supporting the notion that PP1b is mostly present in the longitudinal SR. These data may explain, in part, why PP1b knockdown exhibited the highest impact on cell shortening and the Ca 2+ transient in isolated rat cardiomyocytes. Whether the physical interaction between PLN and PP1b is direct or indirect remains to be investigated. In this regard, the PP1 catalytic subunit is known to be anchored by a specific adaptor protein in the corresponding subcellular component. One such possible partner for PP1b is RGL 22 (also known as Gm), a PP1 glycogen-targeting subunit, rich in the SR, that has been reported to be preferentially associated with PP1b isoforms in skeletal muscles. 23 Together, these data suggest that PP1b and, in part, PP1a regulate local PP1 activity in close proximity of SERCA/PLN via PP1 regulatory proteins without changing whole-cell PP1 activity in cardiomyocytes, as proposed in Figure 6C .
Regarding the high junctional SR-specific distribution of PP1g, we could not determine a significant functional consequence on either Ca 2+ cycling or RyR phosphorylation by the PP1 isoform knockdown experiments. It is conceivable that RyR phosphorylation is thus regulated by multiple PPs. Indeed, the recent characterization of RyR phosphorylation by site-specific antibodies 24 revealed that Ser2808 is controlled by a combination of PP1 and PP2A, whereas Ser2815 is preferentially controlled by PP2A, suggesting that a single PP1 isoform knockdown may have only a minor impact on RyR phosphorylation.
In conclusion, we have demonstrated that PP1b is the most significantly involved PP1 isoform in regulating PLN phosphorylation at Ser16 in the longitudinal SR, thereby controlling SR-mediated Ca 2+ cycling in cardiomyocytes. Because PP1b expression is significantly increased in the failing heart, modulation of its activity may be a potential therapeutic target. Whether PP1b inhibition is beneficial or detrimental to cardiac dysfunction needs to be investigated in future in vivo experimental settings.
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